Cantargia Q2 2024: CAN10 Proof-of-Mechanism - Redeye

Redeye comments on Cantargia's Q2 report. CAN10 is progressing according to plan with proof-of-mechanism established in the single-dose cohorts. The study of nadunolimab in triple-negative breast cancer has been delayed by up to six months with readout now expected by H1 2025.

Länk till analysen i sin helhet: https://www.redeye.se/research/1036048/cantargia-q2-2024-can10-proof-of-mechanism?utm_source=finwire&utm_medium=RSS